menu

Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma

Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.

    Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, dermatologists, oncology nurses, advanced practitioners as well as other clinicians involved in the management of patients with melanoma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Understand the nuances of adjuvant regimens in stage III melanoma which guides treatment choice 
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Jeffrey Weber, MD, PhD, chair for this educational event, has received research funding from BMS, Merck, Incyte, Moderna, Regeneron, and Pfizer; has an ownership interest in Biond, Evaxion, OncoC4, and InstilBio; receives royalties from Moffitt; is a patent holder in Biodesix, and Moffitt; and received consulting fees from BMS, Merck, GSK, Genentech, Pfizer, Regeneron, Incyte, Biond, OncoC4, InstilBio, Moderna, and Evaxion.

    Omid Hamid, MD, faculty for this educational event, has received research funding from Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, Cytomx, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Regeneron, Seattle Genetics, Torque, Zelluna; received consulting fees from Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai Biotech, Roche Genentech, Gerogiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Biotech, Iovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, Zelluna; and has ownership interest in Bactonix. 

    Jason J. Luke, MD, FACP, faculty for this education event,  has served on DSMB for Abbvie, Agenus, Immutep, and Evaxion; served on scientific advisory board for (no stock) 7 Hills, Affivant, BioCytics, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio, (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, STipe, and Tempest; received consulting fees from Abbvie, Agenus, Alnylam, AstraZeneca, Atomwise, Bayer, Bristol-Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Ko Bio Labs, Krystal, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, LegoChem, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimmune, Ribon, Roivant, Servier, STINGthera, Sumoitomo, Synlogic, Synthekine, and Teva; received research support (to the institution for clinical trials) from AbbVie, Astellas, Astrazeneca, Bristol-Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, and Xencor; holds patent US-11638728.

    Sapna Patel, MD, faculty for this educational event, has received research funding from Bristol-Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen, Novartis, Provectus, Seagen, Syntrix Bio, and TriSalus Life Sciences; and received consulting fees from Bristol-Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Immatics, Immunocore, Novartis, Pfizer, Replimune, and TriSalus Life Sciences.

    Ryan Sullivan, MD, faculty for this educational event, has received research funding from Merck, and Novartis; and received consulting fees from BMS, Merck, Novartis, Pfizer, Marengo, and Replimune.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME, LLC. Planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Bristol Myers Squibb and Merck Sharp & Dohme Corp.

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 8/18/2023 through 8/18/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Sep 2023